Asuragen

Overview

Asuragen is a biotechnology company based in the United States, founded in 2006, that specializes in the development of innovative solutions for genetic analysis within the pharmaceutical and service industries. The company operates in the manufacturing sector, focusing on the creation of advanced diagnostic tools and assays. Asuragen's expertise includes the AmplideX® PCR technology, which allows for the highly multiplexed amplification and detection of challenging genetic variants such as triplet repeat alleles, structural variants, single nucleotide variants (SNVs), insertions and deletions (INDELs), and copy number variations (CNVs). Their research and case studies highlight the effectiveness of their assays in resolving complex genotypes associated with various genetic conditions, demonstrating high categorical agreement in detecting pathogenic variants across different platforms, including capillary electrophoresis systems. Asuragen's commitment to addressing the challenges in genetic testing is evident in their published research articles, which contribute to advancements in the field of molecular diagnostics. The company's employee size ranges from 51 to 200, and it reports an annual revenue of approximately $60 million.

Industry